(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 January 2001 (11.01.2001)

PCT

(10) International Publication Number WO 01/01749 A3

(51) International Patent Classification7: A61K 38/10, G01N 33/68, A61P 7/02 C07K 7/08,

(21) International Application Number: PCT/US00/18284

(22) International Filing Date: 30 June 2000 (30.06.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/142,211

2 July 1999 (02.07.1999)

- (71) Applicant: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US).
- (72) Inventors: DENNIS, Mark, S.; 120 Plymouth, San Carlos, CA 94070 (US). EIGENBROT, Charles; 1129 Bernal Avenue, Burlingame, CA 94010 (US). LAZARUS, Robert, A.; 237 Hillcrest Boulevard, Millbrae, CA 94030
- (74) Agents: KUBINEC, Jeffrey, S. et al.; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080-4990 (US).

Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

With international search report.

(88) Date of publication of the international search report: 22 March 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FVIIa ANTAGONISTS

(57) Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.

INTERNATIONAL SEARCH REPORT

Int. Jonal Application No PCT/US 00/18284

A. CLASSIF IPC 7	CO7K7/08 A61K38/10 G01N33/	68 A61P7/02	
According to	International Patent Classification (IPC) or to both national classif	ication and IPC	
	SEARCHED		
Minimum do IPC 7	cumentation searched (classification system followed by classification ${\sf C07K-A61K-G01N}$	ation symbols)	
	ion searched other than minimum documentation to the extent tha		
	ata base consulted during the international search (name of data in BS Data, EPO-Internal, STRAND, WPI		
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the	relevant passages	Relevant to claim No.
P,X	DENNIS, MARK S. ET AL: "Peptide inhibitors of factor VIIa as anticoagulants" NATURE (LONDON) (2000), 404(6777, 465-470, 30 March 2000 (2000-03-30), XPG the whole document	7), 002155500 -/	17-44
X Furl	ther documents are listed in the continuation of box C.	X Patent family members are listed	in annex.
"A" docum consi "E" earlier filing: "L" docum which citatic "O" docum other "P" docum later t	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another on or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but than the priority date claimed	 "T" later document published after the inte or priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the do "Y" document of particular relevance; the cannot be considered to involve an in document is combined with one or moments, such combination being obvious in the art. "&" document member of the same patent 	the application but soon underlying the laimed invention be considered to current is taken alone laimed invention ventive step when the re other such docuust to a person skilled family
	actual completion of the International search 19 December 2000	Date of mailing of the international sea	агсп героп
	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fay: (+31-70) 340-3016	Fuhr, C	

2

INTERNATIONAL SEARCH REPORT

Int. .lonal Application No PCT/US 00/18284

		PC1/U3 U0/10204
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORI, TETSUYA ET AL: "Analysis of promoter activity of 5'-upstream regions of zebrafish olfactory receptor genes" retrieved from STN Database accession no. 132:304194 XP002155502 abstract & BIOL. PHARM. BULL. (2000), 23(2), 165-173, 24 March 2000 (2000-03-24),	17
Ρ,Χ	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ADAMS, MARK D. ET AL: "The genome sequence of Drosophila melanogaster" retrieved from STN Database accession no. 132:275066 XP002155503 abstract & SCIENCE (WASHINGTON, D. C.) (2000), 287(5461), 2185-2195, 24 March 2000 (2000-03-24), XP002155501	17
A	US 5 834 244 A (DENNIS MARK S ET AL) 10 November 1998 (1998-11-10) column 9, line 5 -column 13, line 6; claims	17-44
A	WO 97 20939 A (GENENTECH INC) 12 June 1997 (1997-06-12) claims; examples	17-44

. - \$ -

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-16

Present claims 1-12 relate to a compound defined by reference to a desirable characteristic or property, namely being able to bind to FVIIa.

The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products/compounds/methods/apparatus. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product/compound/method/apparatus by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds claimed for in claims 17-26.

The initial phase of the search based on claims 13-16 revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claim(s) may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claim(s) is impossible. Consequently, the search has been restricted to claims 17-26.

Present claims 27-44 relate to methods and compositions employing compounds of claims 1-26. According to the objections raised above the scope of the claims was restricted to methods and composition employing compounds claimed for in claims 17-26.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. :lonal Application No PCT/US 00/18284

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 5834244	А	10-11-1998	US CA EP JP WO US US	5795954 A 2184058 A 0748380 A 9509838 T 9523860 A 5863893 A 5880256 A	18-08-1998 08-09-1995 18-12-1996 07-10-1997 08-09-1995 26-01-1999 09-03-1999
WO 9720939	Α	12-06-1997	US AU EP US	5736364 A 1023497 A 0866870 A 5874407 A	07-04-1998 27-06-1997 30-09-1998 23-02-1999